AN-2728

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    AN-2728 is an inhibitor of PDE4 with IC50 value of 0.49 μM [1]. PDE4 is a phosphodiesterase and plays an important role in the chronic inflammation associated with psoriasis and atopic dermatitis [2].AN-2728 is a boron-containing, anti-inflammatory, topically administered compound that inhibits PDE4 activity and suppresses the release of TNF-α, IL-23, IL-12 and other cytokines [2]. In cell based assays, AN-2728 inhibited cytokine release of TNF-α, IL-2, IFN-γ, IL-5 and IL-10 with IC50 values of 0.54, 0.61, 0.83, 2.4 and 5.3 μM, respectively [1].AN-2728 was well tolerated and had good therapeutic potential. AN-2728 is now in clinical development for the treatment of psoriasis and atopic dermatitis [2].
    
    [1]. Akama T, Baker SJ, Zhang YK, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett, 2009, 19(8): 2129-2132.
    [2]. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs, 2009, 10(11): 1236-1242.
- Properties
  - Alternative Name
    
    AN2728;AN 2728; 4-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile
    
    CAS Number
    
    906673-24-3
    
    Molecular Formula
    
    C14H10BNO3
    
    Molecular Weight
    
    251.05
    
    Appearance
    
    A solid
    
    Purity
    
    99.33%
    
    Solubility
    
    insoluble in H2O; ≥12.55 mg/mL in DMSO; ≥94.4 mg/mL in EtOH
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

AN-2728

Background

We Also Recommend

Anamorelin

Anguizole

Ansamitocin P-3